Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M Submitted by admin on Fri, 08/25/2017 - 09:53 Read more about Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M Source Endpoints Headline Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M News Tags Novartis Xoma M&A gevokizumab cardiovascular disease
Decimated by clinical failure, Xoma turns to plan B Submitted by admin on Sat, 08/08/2015 - 13:17 Read more about Decimated by clinical failure, Xoma turns to plan B Source Fierce Biotech Headline Decimated by clinical failure, Xoma turns to plan B News Tags Xoma clinical trials gevokizumab XOMA 358 endocrine disorders
Already with $1 billion in losses, Xoma plummets with late-stage drug failure Submitted by admin on Sat, 07/25/2015 - 09:42 Read more about Already with $1 billion in losses, Xoma plummets with late-stage drug failure Source Bizjournals.com Headline Already with $1 billion in losses, Xoma plummets with late-stage drug failure News Tags Xoma gevokizumab Behcet's uveitis
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head Submitted by admin on Wed, 07/22/2015 - 12:08 Read more about Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head Source TheStreet.com Headline Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head News Tags Xoma gevokizumab
3 Biotech Stocks With Upcoming Data That Could Be Huge Submitted by admin on Thu, 01/22/2015 - 09:33 Read more about 3 Biotech Stocks With Upcoming Data That Could Be Huge Source 24/7 Wall St Headline 3 Biotech Stocks With Upcoming Data That Could Be Huge News Tags Aerie Pharma Ocular Therapeutix Xoma gevokizumab Rhopressa OTX-TP
This Week in Biotech: Put It in Print Submitted by admin on Sun, 03/09/2014 - 13:31 Read more about This Week in Biotech: Put It in Print Source Motley Fool Headline This Week in Biotech: Put It in Print News Tags Endo Aveed Rigel Pharmaceuticals R118 Sangamo BioSciences SB-728-T NewLink Genetics Xoma gevokizumab
Xoma to stop testing drug as arthritis treatment Submitted by admin on Tue, 03/04/2014 - 22:23 Read more about Xoma to stop testing drug as arthritis treatment Source Yahoo/Reuters Headline Xoma to stop testing drug as arthritis treatment News Tags Xoma gevokizumab osteoarthritis
XOMA completes enrollment in Phase 2 POC Gevokizumab trial Submitted by admin on Mon, 07/22/2013 - 11:28 Read more about XOMA completes enrollment in Phase 2 POC Gevokizumab trial Source Yahoo/Fly on the Wall Headline XOMA completes enrollment in Phase 2 POC Gevokizumab trial News Tags Xoma gevokizumab osteoarthritis
Biotech Stock Mailbag: 2013 Clinical Trials Calendar Submitted by admin on Fri, 06/07/2013 - 08:07 Read more about Biotech Stock Mailbag: 2013 Clinical Trials Calendar Source TheStreet.com Headline Biotech Stock Mailbag: 2013 Clinical Trials Calendar News Tags Zerenex Xoma Vical Takeda sovaprevir Soluble Ferric Pyrophosphate Rockwell Medical Orexigen MM-398 Merrimack Pharmaceuticals MannKind Keryx GTx GSK gevokizumab enobosarm Coronado Biosciences Contrave CNDO-201 clinical trials ChemoCentryx CCX140 Biodel BIOD-123 Amigal Amicus Therapeutics Alnylam ALN-TTR02 Allovectin Afrezza Achillion ACH-3102
XOMA selects non-infectious anterior scleritis as next indication in POC program Submitted by admin on Mon, 12/31/2012 - 11:26 Read more about XOMA selects non-infectious anterior scleritis as next indication in POC program Source The Fly on the Wall Headline XOMA selects non-infectious anterior scleritis as next indication in POC program News Tags Xoma non-infectious anterior scleritis gevokizumab